274 related articles for article (PubMed ID: 27160359)
1. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Gotthardt D; Loss M; Ladenburger S; Wimmer P; Dworak M; Schlitt HJ
Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
[TBL] [Abstract][Full Text] [Related]
2. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Neuhaus P; Gotthardt D; Loss M; Ladenburger S; Paulus EM; Mertens M; Schlitt HJ
Am J Transplant; 2014 Mar; 14(3):701-10. PubMed ID: 24502384
[TBL] [Abstract][Full Text] [Related]
3. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
4. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
5. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
Nelson LM; Andreassen AK; Andersson B; Gude E; Eiskjær H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
7. Evolution of Renal Function in Renal Allograft Recipients Under Various Everolimus-Based Immunosuppressive Regimens.
Skalioti C; Marinaki S; Darema M; Lionaki S; Antonakopoulos N; Zavos G; Boletis J
Transplant Proc; 2015; 47(6):1705-10. PubMed ID: 26293038
[TBL] [Abstract][Full Text] [Related]
8. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
[TBL] [Abstract][Full Text] [Related]
9. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
[TBL] [Abstract][Full Text] [Related]
10. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
12. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
13. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
Cillo U; Saracino L; Vitale A; Bertacco A; Salizzoni M; Lupo F; Colledan M; Corno V; Rossi G; Reggiani P; Baccarani U; Bresàdola V; De Carlis L; Mangoni I; Ramirez Morales R; Agnes S; Nure E
Liver Transpl; 2019 Feb; 25(2):242-251. PubMed ID: 30592371
[TBL] [Abstract][Full Text] [Related]
14. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
Manzia TM; Angelico R; Toti L; Grimaldi C; Sforza D; Vella I; Tariciotti L; Lenci I; Breshanaj G; Baiocchi L; Tisone G
Transplant Proc; 2018; 50(1):175-183. PubMed ID: 29407305
[TBL] [Abstract][Full Text] [Related]
15. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
[TBL] [Abstract][Full Text] [Related]
16. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
[TBL] [Abstract][Full Text] [Related]
17. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials.
Lee SG; Jeng LB; Saliba F; Singh Soin A; Lee WC; De Simone P; Nevens F; Suh KS; Fischer L; Jin Joo D; Fung J; Joh JW; Kaido T; Grant D; Meier M; Rauer B; Sips C; Kaneko S; Levy G
Transplantation; 2021 Jul; 105(7):1564-1575. PubMed ID: 33741847
[TBL] [Abstract][Full Text] [Related]
20. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.
Saliba F; Duvoux C; Dharancy S; Dumortier J; Calmus Y; Gugenheim J; Kamar N; Salamé E; Neau-Cransac M; Vanlemmens C; Durand F; Pageaux G; Leroy V; Hardwigsen J; Gharbi H; Masson C; Tindel M; Conti F
Liver Transpl; 2019 Dec; 25(12):1822-1832. PubMed ID: 31631501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
